Roche Actemra BLA On Track For Submission This Year
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche expects results of three Phase III studies to support an application for tocilizumab in rheumatoid arthritis.
You may also be interested in...
Roche’s Second Actemra Pivotal Trial Supports Novel IL-6 Inhibitor In Rheumatoid Arthritis
Roche expects two additional Phase III clinical trials evaluating tocilizumab to report later this year.
Roche’s Second Actemra Pivotal Trial Supports Novel IL-6 Inhibitor In Rheumatoid Arthritis
Roche expects two additional Phase III clinical trials evaluating tocilizumab to report later this year.
Roche R&D Model Is Designed To Accelerate Complex Research Organization
Global R&D activities will be centered around five Disease Biology Areas: oncology, virology, inflammation, metabolism and CNS.